Global Dementia Associated with Alzheimer’s Disease Market is estimated to value over USD 6.5 billion by 2026 end and register a CAGR of over 4.3% during the forecast period 2019 to 2026.
Research has demonstrated that the aging population will not show signs of reduction as there are disproportionate fertility rates and a rise in life expectancy. This fluctuation towards the aging population is projected to play a role in the high presence of Alzheimer’s disease which, in turn, will cause a significant burden on health care systems, social care systems and humans alike, on a global scale. Market study predicts that the surge in Alzheimer’s related incidences is projected to augment the demand for improved therapies and innovative drugs.
Within the geriatric population, Alzheimer’s disease (AD) is a major cause for dementia. This, in turn, will lead to a great deal of dependency on other people in the later part of their lives. It is noteworthy that the treatment which is available can only provide aid in the symptoms but there is no known cure for it. The medication that is available cannot be easily acquired and several patients are left with no choice but to suffer without any relief. Hence, there is a dire need for alternative treatments that is both innovative and effective. But fierce competition within the market for common drugs may hamper the global dementia associated with Alzheimer’s disease market growth.
Programs in AD drug development undergo stringent regulations and sanctions. If such a program needs to be conducted, it will have to undertake a period of 13 years from the time of preclinical studies till the time that it gets sanctioned by the FDA. Furthermore, the treatment for altering the effects of Alzheimer’s disease requires many strides and developments but subsequently, encounters many constraints. Such constraints range from insufficient surrogate markers, challenges in selecting ideal groups for clinical trials, as well as the sheer scale and length of time required to conduct such trials. Such factors can negatively affect the global dementia associated with Alzheimer’s disease market size
Among the foremost companies which undertake certain efforts and measures in formulating innovative drug program is the Japanese company known as Ono Pharmaceutical Co. Ltd. They have acquired further approval for the formulation which contains new ingredients which are known as Exelon and Rivastach Patches. Both of these ingredients count as transdermal patches which subdues the penetration of indications linked with mild to moderate dementia attributed to Alzheimer’s
Key players who dominate this market includes Ono Pharmaceutical Co., Eisai Co., Ltd., Johnson & Johnson Services, Inc., Novartis AG, Allergan plc., Merz Pharma GmbH & Co. KGaA., F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Pfizer, Inc., Limited, Ltd, H. Lundbeck A/S.
Global Dementia Associated with Alzheimer’s Disease Market Segmentation:
By Drug Class
- Cholinergic/ Cholinesterase (ChE) Inhibitors
- Donepezil
- Galantamine
- Rivastigmine
- Memantine
- Combined Drug (Memantine & Donepezil) and Others
By Distribution Channel
- Hospital Pharmacies
- Retail
- Online Sales
By Region
- Europe
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
FutureWise Key Takeaways:
- Growth prospects
- SWOT analysis
- Key trends
- Key data-points affecting market growth
Objectives of the Study:
- To provide with an exhaustive analysis on the global dementia associated with Alzheimer’s disease market by drug class, by distribution channel, and by region
- To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
- To evaluate and forecast micro-markets and the overall market
- To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
- To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com